glaxo aims high after profit fall glaxosmithkline saw its profits fall 9 % last year to â£6.2bn ( $ 11.5bn ) , but europe 's biggest drugmaker says a recovery during 2005 is on the way . cheap copies of its drugs , particularly anti-depressants paxil and wellbutrin , and a weak dollar had hit profits , but global sales were up 1 % in 2004 . the firm is confident its new drug pipeline will deliver profits despite the failure of an obesity drug . chief executive jean-pierre garnier said it had been a `` difficult year '' . in early afternoon trade in london the company share price was down 1 % at 1218 pence . mr garnier said the company had absorbed over â£1.5bn of lost sales to generics but still managing to grow the business . `` the continuing success of our key products means we can now look forward to a good performance in 2005 , '' he said . `` 2005 will also be an important year in terms of research and development pipeline progress . '' however , the firm discontinued development of an experimental treatment for obesity , known as '771 , after disappointing clinical trial results . glaxo is relying on new treatments for conditions such as cancer , diabetes , depression , hiv/aids and allergies to lift the pace of sales growth after several disappointing years .